JP6868060B2 - 皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 - Google Patents
皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 Download PDFInfo
- Publication number
- JP6868060B2 JP6868060B2 JP2019114564A JP2019114564A JP6868060B2 JP 6868060 B2 JP6868060 B2 JP 6868060B2 JP 2019114564 A JP2019114564 A JP 2019114564A JP 2019114564 A JP2019114564 A JP 2019114564A JP 6868060 B2 JP6868060 B2 JP 6868060B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- therapeutic effect
- producing
- kiku
- chrysanthemum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 133
- 208000017520 skin disease Diseases 0.000 title claims description 99
- 230000001225 therapeutic effect Effects 0.000 title claims description 74
- 238000004519 manufacturing process Methods 0.000 title claims description 57
- 239000008194 pharmaceutical composition Substances 0.000 title description 18
- 241000723353 Chrysanthemum Species 0.000 claims description 88
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 88
- 239000002244 precipitate Substances 0.000 claims description 42
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 35
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 35
- 108010060309 Glucuronidase Proteins 0.000 claims description 31
- 102000053187 Glucuronidase Human genes 0.000 claims description 31
- 102000004157 Hydrolases Human genes 0.000 claims description 30
- 108090000604 Hydrolases Proteins 0.000 claims description 30
- 238000006911 enzymatic reaction Methods 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 102000004366 Glucosidases Human genes 0.000 claims description 22
- 108010056771 Glucosidases Proteins 0.000 claims description 22
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 22
- 235000008714 apigenin Nutrition 0.000 claims description 22
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 22
- 229940117893 apigenin Drugs 0.000 claims description 22
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 21
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 21
- 235000009498 luteolin Nutrition 0.000 claims description 21
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 108010093031 Galactosidases Proteins 0.000 claims description 4
- 102000002464 Galactosidases Human genes 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 68
- 229960002751 imiquimod Drugs 0.000 description 65
- 102000004190 Enzymes Human genes 0.000 description 35
- 108090000790 Enzymes Proteins 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 34
- 239000006071 cream Substances 0.000 description 32
- 239000003981 vehicle Substances 0.000 description 32
- 239000002674 ointment Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 101100243745 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ptb1 gene Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 9
- 240000005250 Chrysanthemum indicum Species 0.000 description 9
- -1 opalescents Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000000287 crude extract Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 7
- 201000004681 Psoriasis Diseases 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 239000006049 herbal material Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 230000035618 desquamation Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006208 topical dosage form Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000195940 Bryophyta Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 206010040799 Skin atrophy Diseases 0.000 description 3
- 241000250966 Tanacetum cinerariifolium Species 0.000 description 3
- 229940060265 aldara Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000011929 mousse Nutrition 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- IVCZEZUJCMWBBR-UHFFFAOYSA-N 7-O-beta-D-glucopyranosyl-7,3',4'-trihydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 IVCZEZUJCMWBBR-UHFFFAOYSA-N 0.000 description 2
- 101710099628 Beta-glucosidase 1 Proteins 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 235000017372 Piretro di Dalmazia Nutrition 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 102000046768 human CCL2 Human genes 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 2
- QZOVLVSTWSTHQN-UHFFFAOYSA-N luteolin 7-O-glucoside Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(C(=O)c3c2)c4ccc(O)c(O)c4)C(O)C(O)C1O QZOVLVSTWSTHQN-UHFFFAOYSA-N 0.000 description 2
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010033898 parapsoriasis Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 101710100419 Alpha-galactosidase 1 Proteins 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 108010061261 alpha-glucuronidase Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 150000003754 zirconium Chemical class 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
[1]皮膚疾患の治療効果を有するキク(Chrysanthemum morifolium)抽出物の作製方法であって、
(a)抽出溶媒を用いてキクに抽出工程を行って抽出液を得るステップと、
(b)少なくとも1つの糖質加水分解酵素を前記抽出液に加え、酵素反応を起こして沈殿物を生成するステップと、
を含み、
前記少なくとも1つの糖質加水分解酵素が、グルコシダーゼ、ガラクトシダーゼおよびグルクロニダーゼからなる群より選ばれた少なくとも1つであって、
前記沈殿物が前記皮膚疾患の治療効果を有するキク抽出物である、
皮膚疾患の治療効果を有するキク抽出物の作製方法。
(i)前記沈殿物をアルコール溶媒で再溶解して混合溶液を作製するステップであって、前記混合溶液が溶液部分および不溶物を含む、ステップと、
(ii)前記溶液部分に濃縮および乾燥プロセスを行って洗浄した沈殿物を得るステップと、
を含む、[19]に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
ルテオリン、および
アピゲニン
を少なくとも含む皮膚疾患の治療効果を有するキク抽出物であって、
前記ルテオリンおよび前記アピゲニンの含有量の和が約15〜85wt%である、皮膚疾患の治療効果を有するキク抽出物。
本開示は、皮膚疾患の治療効果を有するキク抽出物の作製方法を提供する。本明細書に記載される皮膚疾患に特定の限定はなく、例として皮膚炎(例えばアレルギー性または接触性)、免疫疾患(例えば乾癬)、感染性皮膚疾患(例えば細菌、真菌、ウィルス感染)であり得る。
したがって、本開示が、任意の上述した本開示の皮膚疾患の治療効果を有するキク抽出物の作製方法により得られる、皮膚疾患の治療効果を有するキク抽出物をも提供できることが理解され得る。
加えて、本開示は、皮膚疾患を治療するのに用いる医薬組成物をさらに提供する。本開示の皮膚疾患を治療するのに用いる医薬組成物は、任意の上述した本開示の皮膚疾患の治療効果を有するキク抽出物と、薬学的に許容されるビヒクル、担体または塩と、を含み得る。
粗抽出物PTB1の作製
酵素処理抽出物PTBXの作製
1.PTBX軟膏の作製
酵素処理前後におけるキク抽出物の化学成分の変化
酵素処理前後のキク抽出物の生物活性の変化
マウスの類乾癬の皮膚炎に対する酵素処理抽出物PTBXの軽減効果の評価
酵素処理プロセスの研究(investigation):酵素と抽出物との比率
酵素処理プロセスの研究:酵素の組み合わせ
酵素処理プロセスの研究:キク属の異なる植物
Claims (21)
- 皮膚疾患の治療効果を有するキク(Chrysanthemum morifolium)抽出物の作製方法であって、
(a)抽出溶媒を用いてキクに抽出工程を行って抽出液を得るステップと、
(b)少なくとも1つの糖質加水分解酵素(glycoside hydrolases)を前記抽出液に加え、酵素反応を起こしてルテオリンおよびアピゲニンの含有量が高まった沈殿物を生成するステップと、
を含み、
前記少なくとも1つの糖質加水分解酵素が、グルコシダーゼ、ガラクトシダーゼおよびグルクロニダーゼからなる群より選ばれた少なくとも1つであって、
前記沈殿物が前記皮膚疾患の治療効果を有するキク抽出物である、
皮膚疾患の治療効果を有するキク抽出物の作製方法。 - 前記抽出溶媒が水またはアルコールを含む、請求項1に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記抽出工程の温度が70〜100℃である、請求項1または2に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記抽出工程に要する時間が1〜3時間である、請求項1〜3のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記少なくとも1つの糖質加水分解酵素がグルコシダーゼであり、前記グルコシダーゼがβ-グルコシダーゼである、請求項1〜4のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記少なくとも1つの糖質加水分解酵素がグルコシダーゼおよびグルクロニダーゼであり、かつ前記グルコシダーゼがβ-グルコシダーゼであり、前記グルクロニダーゼがβ-グルクロニダーゼである、請求項1〜4のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記少なくとも1つの糖質加水分解酵素と前記キクとの重量比が1:200〜10000である、請求項1〜6のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記酵素反応の温度が25〜45℃である、請求項1〜7のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記酵素反応に要する時間が5〜30時間である、請求項1〜8のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記抽出液が水である、請求項1〜4、7〜9のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記抽出工程の温度が70〜100℃である、請求項10に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記少なくとも1つの糖質加水分解酵素がβ-グルコシダーゼである、請求項10または11に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記β-グルコシダーゼと前記キクとの重量比が1:200〜10000である、請求
項12に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。 - 前記少なくとも1つの糖質加水分解酵素がβ-グルコシダーゼおよびβ-グルクロニダーゼである、請求項10または11に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記β−グルコシダーゼおよび前記β−グルクロニダーゼと前記キクとの重量比が1:200〜10000である、請求項14に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記β−グルコシダーゼと前記β−グルクロニダーゼとの重量比が1〜2:1〜2である、請求項14に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記ステップ(b)において、前記酵素反応の後、冷却工程をさらに行って沈殿物の生成を促進する、請求項1〜16のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記冷却工程の温度が約2〜15℃であり、前記冷却工程に要する時間が2〜24時間である、請求項17に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記ステップ(b)の後に、前記沈殿物に洗浄工程を行うステップをさらに含む請求項1〜18のいずれか1項に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
- 前記洗浄工程が、
(i)前記沈殿物をアルコール溶媒で再溶解して混合溶液を作製するステップであって、前記混合溶液が溶液部分および不溶物を含む、ステップと、
(ii)前記溶液部分に濃縮および乾燥プロセスを行って洗浄した沈殿物を得るステップと、
を含む、請求項19に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。 - 前記アルコール溶媒がメタノールまたはエタノールを含む、請求項20に記載の皮膚疾患の治療効果を有するキク抽出物の作製方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019114564A JP6868060B2 (ja) | 2019-06-20 | 2019-06-20 | 皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019114564A JP6868060B2 (ja) | 2019-06-20 | 2019-06-20 | 皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021001127A JP2021001127A (ja) | 2021-01-07 |
JP6868060B2 true JP6868060B2 (ja) | 2021-05-12 |
Family
ID=73993825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019114564A Active JP6868060B2 (ja) | 2019-06-20 | 2019-06-20 | 皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6868060B2 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0585934A (ja) * | 1991-09-25 | 1993-04-06 | Sumitomo Metal Ind Ltd | 抗トリプシン剤 |
JP2958296B2 (ja) * | 1998-02-27 | 1999-10-06 | 株式会社トキワ漢方製薬 | 野菊花に含まれる新規化合物およびこれを含む機能性食品 |
JP2007197345A (ja) * | 2006-01-25 | 2007-08-09 | Ja Agurin Yamagata:Kk | 菊を含有する水性懸濁組成物 |
JP6307760B2 (ja) * | 2012-12-11 | 2018-04-11 | 池田食研株式会社 | セリ科植物エキスの製造方法 |
JP6358418B2 (ja) * | 2013-09-26 | 2018-07-18 | 池田食研株式会社 | シソ科植物エキスの製造方法 |
JP6452104B2 (ja) * | 2014-05-02 | 2019-01-16 | オリザ油化株式会社 | フィブロネクチン発現促進剤 |
EP3590361A4 (en) * | 2017-10-05 | 2021-01-27 | Petroeuroasia Co., Ltd. | COMPOSITION CONTAINING LUTEOLIN AND ITS MANUFACTURING PROCESS |
-
2019
- 2019-06-20 JP JP2019114564A patent/JP6868060B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2021001127A (ja) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8496917B2 (en) | Compositions and methods for improving skin appearance | |
EP3889249A1 (en) | Exosome and various uses thereof | |
KR101578342B1 (ko) | 주름을 방지 또는 개선하기 위한 경구, 주사, 피부 외용제 및 미용 방법 | |
US20050129618A1 (en) | Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell factor | |
KR102267796B1 (ko) | 천연 추출물 유래 엑소좀을 유효성분으로 포함하는 피부 진정용 조성물 | |
JPH0873342A (ja) | 覆盆子抽出物含有皮膚外用剤または浴用剤 | |
KR102041876B1 (ko) | 칸나비디올 또는 그 유도체를 함유하는 아토피 개선용 화장료 조성물 | |
US20130183257A1 (en) | Compositions and methods for improving skin appearance | |
TWI684456B (zh) | 製備具有治療皮膚疾病功效之杭菊萃取物的方法、具有治療皮膚疾病功效的杭菊萃取物以及含此萃取物之醫藥組成物 | |
WO2007081190A1 (en) | Novel use of 1,2,3,4,6-penta-o-galloyl-beta-d-glucose | |
KR101347910B1 (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품 조성물, 화장료 조성물 및 약학 조성물 | |
JP6868060B2 (ja) | 皮膚疾患の治療効果を有するキク抽出物の作製方法、皮膚疾患の治療効果を有するキク抽出物、およびその抽出物を含む医薬組成物 | |
CN112386655A (zh) | 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途 | |
KR20110018067A (ko) | 피부 각질 줄기세포 증식용 조성물 | |
CN115487108A (zh) | 一种具有抗氧化活性的半胱天冬酶-1活性抑制剂及其应用 | |
US10987394B2 (en) | Method for preparing an extract of Chrysanthemum morifolium with an effect of treating skin diseases, extract of Chrysanthemum morifolium with an effect of treating skin diseases and pharmaceutical composition containing the extract | |
CN114344289A (zh) | 一种具有抗衰老活性的组合物及其制剂和用途 | |
JP5732641B2 (ja) | 肝細胞増殖因子産生促進剤 | |
KR100525722B1 (ko) | 피부외용제 | |
KR20140013796A (ko) | 진세노사이드 f1을 유효 성분으로 포함하는 피부 염증질환 개선용 화장료 조성물 | |
KR20140073873A (ko) | 유제놀 유도체를 함유하는 아토피성 피부염의 치료용 약제학적 조성물 및 그 제조방법 | |
EP1009378A1 (fr) | Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
US11052098B2 (en) | Composition containing araloside for external application to skin | |
WO2024100919A1 (ja) | スフィンゴイド塩基を含む掻痒抑制に用いるための剤およびその用途 | |
KR101583478B1 (ko) | 항자극용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201113 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210316 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6868060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |